Health care articles from across Nature Portfolio

In 2024, there were major advances in inflammatory bowel disease research. Treatment strategies with biologic agents for inflammatory bowel disease matured, and gut microbiota–bacteriophage–host interaction emerged as a new frontier to target.

Pre-eclampsia is a common and dangerous pregnancy-related illness. Using tiny lipid particles to deliver messenger RNA directly to the placenta to boost blood-vessel function might prove to be an effective treatment.

The protein GDF-15 is a potent immunosuppressor that is overexpressed in many solid tumours and impedes the effects of cancer immunotherapy. In a first-in-human clinical trial, the GDF-15-targeting antibody visugromab reversed GDF-15-mediated resistance to immunotherapy, resulting in deep, long-lasting tumour regressions in some individuals.

Histological slides often contain artifacts that affect the performance of downstream image analysis. Here, the authors present GrandQC, a tool that enables high-precision tissue and artifact segmentation in histological slides. This tool can be used to monitor sample preparation and scanning quality across pathology departments.

In 2024, there were major advances in inflammatory bowel disease research. Treatment strategies with biologic agents for inflammatory bowel disease matured, and gut microbiota–bacteriophage–host interaction emerged as a new frontier to target.

Current regulatory frameworks for artificial intelligence-based clinical decision support (AICDS) are insufficient to ensure safety, effectiveness, and equity at the bedside. The oversight of clinical laboratory testing, which requires federal- and hospital-level involvement, offers many instructive lessons for how to balance safety and innovation and warnings regarding the fragility of this balance. We propose an AICDS oversight framework, modeled after clinical laboratory regulation, that is deliberative, inclusive, and collaborative.

The United States has moved to deracialize kidney diagnostics. The move addresses major health-equity issues — but it also shines a light on a problematic clinical test.